Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

Evaluation of Pain Sensitization in Rheumatoid Arthritis: Analysis on a Cohort of Tofacitinib Treated PatientsCompleted
NCT03815578NAUpdated May 6, 2023
Sponsor: University Hospital, Bordeaux
Rheumatoid Arthritis
France
Fall Prevention in Older Adults With OABCompleted
NCT03946124Phase 4Updated May 6, 2023
Sponsor: University of Pennsylvania
Overactive Bladder
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)Completed
NCT00716625N/AUpdated May 3, 2023
Sponsor: Pfizer
Carcinoma, Renal Cell
National Trends in Otitis Media in Children Under 5 Years of AgeCompleted
NCT01339546N/AUpdated May 3, 2023
Sponsor: Pfizer
Otitis Media · Myringotomy Tube Insertion · Skin Rash · Trauma
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) TreatmentsCompleted
NCT04175262N/AUpdated May 3, 2023
Sponsor: Pfizer
Metastatic Renal Cell Carcinoma (mRCC)
Canada
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular CarcinomaTerminated
NCT05249569Phase 2Updated May 3, 2023
Sponsor: University of Texas Southwestern Medical Center
Hepatocellular Carcinoma
United States
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.Completed
NCT04535167Phase 1Updated May 3, 2023
Sponsor: Pfizer
Viral Disease
United States, Belgium, Brazil, Spain
Evaluating Quality of Life of AF Patients Following a BleedCompleted
NCT04921176N/AUpdated Apr 28, 2023
Sponsor: Swansea University
Atrial Fibrillation
United Kingdom
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and OutcomesTerminated
NCT04396626N/AUpdated Apr 27, 2023
Sponsor: Pfizer
Breast Cancer
United States
Vfend Special Investigation For ProphylaxisCompleted
NCT02674685N/AUpdated Apr 25, 2023
Sponsor: Pfizer
Fungal Infection
Randomized Trial in Adult Participants With Acute MigrainesCompleted
NCT04571060Phase 3Updated Apr 24, 2023
Sponsor: Pfizer
Migraine
United States
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese InfantsCompleted
NCT04530838Phase 3Updated Apr 21, 2023
Sponsor: Pfizer
Pneumococcal Disease
Japan
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid LeukemiaCompleted
NCT03416179Phase 3Updated Apr 21, 2023
Sponsor: Pfizer
Leukemia, Myeloid, Acute
United States, Australia, Austria, Belgium, Canada +17 more
Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme BorreliosisCompleted
NCT03970733Phase 2Updated Apr 21, 2023
Sponsor: Pfizer
Lyme Borreliosis
United States
Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile CarcinomaUnknown
NCT03774901Phase 2Updated Apr 21, 2023
Sponsor: Centre Hospitalier Universitaire de Besancon
Penile Cancer · Penile Neoplasms · Penile Squamous Cell Carcinoma
France
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization ScheduleCompleted
NCT00460486Phase 3Updated Apr 19, 2023
Sponsor: Pfizer
Encephalitis, Tick-Borne
Poland
A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher DiseaseCompleted
NCT01422187Phase 3Updated Apr 19, 2023
Sponsor: Pfizer
Gaucher Disease
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese ParticipantsWithdrawn
NCT05061277Phase 1Updated Apr 18, 2023
Sponsor: Pfizer
Healthy
China
a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From ChinaCompleted
NCT05546125N/AUpdated Apr 18, 2023
Sponsor: Pfizer Pharmaceuticals Ltd.
Pulmonary Arterial Hypertension (PAH)
China
MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of AgeCompleted
NCT04440163Phase 3Updated Apr 18, 2023
Sponsor: Pfizer
Meningococcal Vaccine
United States, Czechia, Denmark, Hungary, Poland
Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic SteatohepatitisCompleted
NCT04399538Phase 2Updated Apr 13, 2023
Sponsor: Pfizer
Nonalcoholic Steatohepatitis · Nonalcoholic Fatty Liver Disease
United States, Canada
Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of AgeCompleted
NCT05096208Phase 3Updated Apr 12, 2023
Sponsor: Pfizer
RSV
United States
Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community PracticeCompleted
NCT04297384NAUpdated Apr 10, 2023
Sponsor: Roswell Park Cancer Institute
Anatomic Stage IV Breast Cancer AJCC v8 · Breast Carcinoma · Metastatic Breast Carcinoma · Prognostic Stage IV Breast Cancer AJCC v8
United States
Participatory Action Research to Evaluate the Delivery of the MISSION ABC Service Model and Assess Health Service and Clinical OutcomesCompleted
NCT03096509N/AUpdated Apr 7, 2023
Sponsor: Portsmouth Hospitals NHS Trust
COPD · Asthma · Breathlessness
United Kingdom
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATECompleted
NCT04413617Phase 2Updated Apr 7, 2023
Sponsor: Pfizer
Rheumatoid Arthritis
Bulgaria, Canada, Chile, Czechia, Georgia +5 more

Previous page Next page